Format

Send to

Choose Destination
Parkinsonism Relat Disord. 2019 Dec;69:119-124. doi: 10.1016/j.parkreldis.2019.11.009. Epub 2019 Nov 11.

Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.

Author information

1
University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Sarah.Horn@uphs.upenn.edu.
2
University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: rhayley@pennmedicine.upenn.edu.
3
University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: sxie@pennmedicine.upenn.edu.
4
University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Daniel.Weintraub@uphs.upenn.edu.
5
University of Pennsylvania, 330 South 9th Street, Philadelphia, PA, 19107, USA. Electronic address: Nabila.Dahodwala@uphs.upenn.edu.

Abstract

INTRODUCTION:

Psychosis is common among patients with Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Limited data exist on the most effective therapies.

METHODS:

Retrospective cohort study comparing patients with PD or DLB initiated on quetiapine or pimavanserin for psychosis. Primary outcome was time to discontinuation of pimavanserin or quetiapine using Kaplan-Meier survival analysis. We hypothesized the rate of antipsychotic discontinuation would be lower in the pimavanserin group. Subjects were included if the indication for treatment was psychosis and excluded if there was a history of major mental illness or no follow up data were available.

RESULTS:

Forty-seven patients were included in the quetiapine cohort and 45 in the pimavanserin cohort. Patients in the pimavanserin cohort were more likely to have a diagnosis of DLB (33% vs. 11%, P = 0.01) and to have been prescribed an antipsychotic previously (62% vs. 6%, P < 0.01); otherwise, the groups were similar. Time to discontinuation analysis, which accounts for efficacy, safety and tolerability, revealed a lower early pimavanserin discontinuation rate and a higher late pimavanserin discontinuation rate (HR < 1 before day 43, HR > 1 after day 43; P = 0.04). There was no difference in mortality in the pimavanserin group compared to the quetiapine group (HR 0.37, 95% CI 0.06 to 2.45; P = 0.88). More individuals had a documented secondary indication for taking quetiapine than pimavanserin (38% vs. 4%; P = 0.001).

CONCLUSION:

Accounting for efficacy, safety and tolerability, pimavanserin may be more clinically useful for promptly managing psychosis, while quetiapine may confer additional secondary benefits long-term.

KEYWORDS:

Dementia with Lewy bodies; Parkinson's disease; Pimavanserin; Psychosis; Quetiapine

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center